PLRX
Pliant Therapeutics, Inc.
Biotechnology · Healthcare · United States
0.86
close · 2026-10-30
value
4
cheaper than peers4
quality
41
stronger fundamentals41
ranked against
Biotechnology (pre-revenue)
value
quality
109 peerswide variation
Value inputs
| measure | company | vs peers |
| price to book | 0.36× | 99 |
| EV to EBITDA | 0.65× | 56 |
| earnings yield, 2 years ago | -320.2% | 10 |
| earnings yield, 3 years ago | -342.3% | 9 |
| cash flow yield, 2 years ago | -220.5% | 6 |
| earnings yield, latest year | -282.9% | 5 |
| earnings yield, 1 year ago | -404.0% | 5 |
| cash flow yield, 3 years ago | -181.2% | 4 |
| cash flow yield, latest year | -242.0% | 3 |
| cash flow yield, 1 year ago | -299.6% | 3 |
10 of 12 measures available
Quality inputs
| measure | company | vs peers |
| return on equity | -50.3% | 63 |
| operating margin | 0.0% | 50 |
| debt to equity | 19.6% | 26 |
3 of 4 measures available
Facts
| market cap | $53M |
| free cash flow | -$42.5M |
| employees | 49 |
| first trade | 2020-06-03 |
| next earnings | 2026-11-12 |
| fundamentals updated | 2026-08-28 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -2.43 | -3.47 | -2.75 | -2.94 |
| free cash flow | -$128.7M | -$159.4M | -$117.3M | -$96.4M |
| net income | -$149.3M | -$210.3M | -$161.3M | -$123.3M |
| revenue | $0 | $0 | $1.6M | $9.7M |
| unusual items | -$1.8M | $0 | not reported | not reported |